What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer.

Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you. It is not known if LUMAKRAS® is safe and effective in children.

For US Audiences Only Approved Use Patient Information Full Prescribing Information Important Safety Information Select Cancer Type For Health Care Professionals

You are about to leave the lumakras.com/nsclc website and enter a website operated by a third party. Amgen is not responsible for and does not endorse or control the content contained on this third-party website.

Continue
Laurie S., a smiling current LUMAKRAS® patient

What is LUMAKRAS®?

Your lung cancer may be driven by a biomarker mutation and there may be therapies specifically for those mutations.”

Patient story represents individual’s experience with LUMAKRAS®. Results may vary.

– Laurie S.
current LUMAKRAS® patient

How does LUMAKRAS® work to treat non-small cell lung cancer (NSCLC)?

mutation-on

Tumors with the KRAS G12C mutation remain stuck in the “on” position. This causes cells to grow without stopping1,2

KRAS G12C is a specific mutation in the KRAS gene

LUMAKRAS® targets the KRAS G12C mutation and locks it in the “off” position. This may help prevent tumor cell growth3

If your NSCLC is KRAS G12C positive and you have received treatment for it before, ask your doctor if LUMAKRAS® may be able to help3

How did LUMAKRAS® work in the trial?

In a clinical trial, 126 adults with NSCLC were given an oral treatment called LUMAKRAS®. The trial evaluated how many adults with NSCLC responded to LUMAKRAS®, meaning their tumors either shrank or disappeared from initial scan. The trial also measured how long the tumor responded to LUMAKRAS®3

More than 1 in 3 people taking LUMAKRAS® saw their tumor shrink3,*

36-percent-icon

of people saw their tumor shrink* or disappear3

*At least 30%.4

10-month-icon

was the median time a patient’s tumor did not grow or spread to other parts of the body3

These results were based on 45 people, of which 2 people saw their tumor completely disappear, and 43 people who saw their tumor partially shrink3,4

Important Considerations: The approval of LUMAKRAS® in these patients is based on a study that measured the size of tumor shrinkage.3

LUMAKRAS® is the first medicine for KRAS G12C cancer to be studied, and it was tested in the largest KRAS G12C study to date. Talk to your doctor to see if LUMAKRAS® is right for you5
Desiree H., a current LUMAKRAS® patient
[My doctor] told me about LUMAKRAS®, that it was for the specific mutation I have.”

– Desiree H.
current LUMAKRAS® patient

Patient story represents individual’s experience with LUMAKRAS®. Results may vary.

What are the possible side effects of LUMAKRAS®?

When taking any medication, it’s important to be aware of any side effects that you may experience. Talk to your doctor immediately if you notice any side effects so they can make an appropriate decision about further treatment6

LUMAKRAS® may cause serious side effects, including:6

  • Liver problems: LUMAKRAS® may cause abnormal liver blood test results. Your doctor should do blood tests before starting and during treatment with LUMAKRAS® to check your liver function
    • Tell your doctor right away if you get any signs or symptoms of liver problems. These may include: your skin or the white part of your eyes turn yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen)
  • Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your health care provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever
If you experience any of these side effects while taking LUMAKRAS®, you should call your doctor right away6

Not actual patient.

older man taking medication

The most common side effects of LUMAKRAS® include:6

  • Diarrhea
  • Muscle or bone pain
  • Nausea
  • Tiredness
  • Cough
  • Changes in certain blood tests

These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Amgen at 1-800-772-6436 (1-800-77-AMGEN)6

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

  • Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
    • have liver problems.
    • have lung or breathing problems other than lung cancer.
    • are pregnant or plan to become pregnant. It is not known if LUMAKRAS® will harm your unborn baby.
    • are breastfeeding or plan to breastfeed. It is not known if LUMAKRAS® passes into your breast milk. Do not breastfeed during treatment with LUMAKRAS® and for 1 week after the final dose.
  • Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, dietary and herbal supplements. LUMAKRAS® can affect the way some other medicines work, and some other medicines can affect the way LUMAKRAS® works.
  • Especially tell your healthcare provider if you take antacid medicines, including Proton Pump Inhibitor (PPI) medicines or H2 blockers during treatment with LUMAKRAS®. Ask your healthcare provider if you are not sure.

LUMAKRAS® may cause serious side effects, including:

  • Liver Problems: LUMAKRAS® may cause abnormal liver blood test results. Your healthcare provider should do blood tests before starting and during treatment with LUMAKRAS® to check liver function. Tell your healthcare provider right away if you get any signs or symptoms of liver problems, including: your skin or the white part of your eyes turns yellow (jaundice), dark or “tea-colored” urine, light-colored stools (bowel movements), tiredness or weakness, nausea or vomiting, bleeding or bruising, loss of appetite, and pain, aching, or tenderness on the right side of your stomach-area (abdomen).
  • Lung or breathing problems: LUMAKRAS® may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever.
  • Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with LUMAKRAS® if you develop side effects.

The most common side effects

  • The most common side effects of LUMAKRAS® include diarrhea, muscle or bone pain, nausea, tiredness, liver problems, cough, changes in liver function tests, and changes in certain blood tests.
  • These are not all the possible side effects of LUMAKRAS®. Call your doctor for medical advice about side effects.

What is LUMAKRAS®?

LUMAKRAS® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery, and whose tumor has an abnormal KRAS G12C gene, and who have received at least one prior treatment for their cancer. Your healthcare provider will perform a test to make sure that LUMAKRAS® is right for you. It is not known if LUMAKRAS® is safe and effective in children.

Please see LUMAKRAS® full Prescribing Information.

References: 1. NCI Dictionary of Cancer Terms. www.cancer.gov. Accessed January 27, 2025. 2. LUMAKRAS® (sotorasib) prescribing information, Amgen. 3. Ryan MB, et al. Nat Rev Clin Oncol. 2018;15:709-720. 4. Hong DS, et al. N Engl J Med. 2020;383:1207-1217. 5. Data on file, Amgen; [Analysis of AACR Genie v12].

References: 1. Hong DS, et al. N Engl J Med. 2020;383:1207-1217. 2. NCI Dictionary of Cancer Terms. www.cancer.gov. Accessed January 27, 2025. 3. LUMAKRAS® (sotorasib) prescribing information, Amgen. 4. Sotorasib CSR. Amgen; 2021. 5. Data on file, Amgen; [KRAS G12C Trials Sites]. 6. LUMAKRAS® (sotorasib) patient information, Amgen.

References: 1. LUMAKRAS® (sotorasib) patient information, Amgen. 2. LUMAKRAS® (sotorasib) prescribing information, Amgen. 3. Data on file, Amgen; [Sotorasib Tablet Size].

Important Safety Information

What should I tell my healthcare provider before taking LUMAKRAS®?

  • Before taking LUMAKRAS®, tell your healthcare provider about all your medical conditions, including if you:
    • have liver problems.
    • have lung or breathing problems other than lung cancer.